Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

285 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia.
Wang ES, Aplenc R, Chirnomas D, Dugan M, Fazal S, Iyer S, Lin TL, Nand S, Pierce KJ, Shami PJ, Vermette JJ, Abboud CN. Wang ES, et al. Among authors: aplenc r. Leuk Lymphoma. 2020 Aug;61(8):1965-1973. doi: 10.1080/10428194.2020.1742897. Epub 2020 May 20. Leuk Lymphoma. 2020. PMID: 32432489 Free article.
Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
Aplenc R, Alonzo TA, Gerbing RB, Lange BJ, Hurwitz CA, Wells RJ, Bernstein I, Buckley P, Krimmel K, Smith FO, Sievers EL, Arceci RJ; Children's Oncology Group. Aplenc R, et al. J Clin Oncol. 2008 May 10;26(14):2390-3295. doi: 10.1200/JCO.2007.13.0096. J Clin Oncol. 2008. PMID: 18467731 Free PMC article. Clinical Trial.
Gene expression profiling to predict viridans group streptococcal and invasive fungal infection in pediatric acute myeloid leukemia: a brief report from the Children's Oncology Group.
Lee GE, Sung L, Fisher BT, Sullivan KE, McWilliams T, Tobias JW, Meshinchi S, Alonzo TA, Gamis A, Aplenc R. Lee GE, et al. Among authors: aplenc r. Acta Haematol. 2014;131(3):167-9. doi: 10.1159/000353758. Epub 2013 Nov 6. Acta Haematol. 2014. PMID: 24217778 Free PMC article. No abstract available.
Predictors of antiemetic alteration in pediatric acute myeloid leukemia.
Freedman JL, Faerber J, Kang TI, Dai D, Fisher BT, Huang YS, Li Y, Aplenc R, Feudtner C. Freedman JL, et al. Among authors: aplenc r. Pediatr Blood Cancer. 2014 Oct;61(10):1798-805. doi: 10.1002/pbc.25108. Epub 2014 Jun 17. Pediatr Blood Cancer. 2014. PMID: 24939039 Free PMC article.
A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology Group.
Miller TP, Getz KD, Kavcic M, Li Y, Huang YS, Sung L, Alonzo TA, Gerbing R, Daves M, Horton TM, Pulsipher MA, Pollard J, Bagatell R, Seif AE, Fisher BT, Gamis AS, Aplenc R. Miller TP, et al. Among authors: aplenc r. Leuk Lymphoma. 2016 Jul;57(7):1567-74. doi: 10.3109/10428194.2015.1088652. Epub 2016 Jan 4. Leuk Lymphoma. 2016. PMID: 26727639 Free PMC article.
CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531.
Pollard JA, Loken M, Gerbing RB, Raimondi SC, Hirsch BA, Aplenc R, Bernstein ID, Gamis AS, Alonzo TA, Meshinchi S. Pollard JA, et al. Among authors: aplenc r. J Clin Oncol. 2016 Mar 1;34(7):747-55. doi: 10.1200/JCO.2015.62.6846. Epub 2016 Jan 19. J Clin Oncol. 2016. PMID: 26786921 Free PMC article. Clinical Trial.
285 results